Ebola drug trial: a ray of hope

References (6)

1. Jadav SS, Kumar A, Ahsan MJ, Jayaprakash V. Ebola virus: current and future perspectives: Infect Disord Drug Targets. 2015;15:20-31
2. Misasi J, Gilman MSA, Kanekiyo M, Gui M, Cagigi A, Mulangu S et al., Structural and molecular basis for Ebola virus neutralization by protective human antibodies: Science. 2016;351:1343–6
3. Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio. 2018;9:e00221-18
4. Madelain V, Baize S, Jacquot F, Reynard S, Fizet A, Barron S et al. Ebola viral dynamics in nonhuman primates provides insights into virus immunopathogenesis and antiviral strategies. Nat Commun. 2018;9:4013
5. McCarthy M. US signs contract with ZMapp maker to accelerate development of the Ebola drug. BMJ. 2014;349:g5488
6. Davey RT Jr, Dodd L, Proschan MA, Neaton J, Neuhaus Nordwall J, Koopmeiners JS. A randomized, controlled trial of ZMapp for Ebola virus infection. The PREVAIL II Writing Group, for the Multi-National PREVAIL II Study Team. N Engl J Med. 2016;375:1448-56.